Chronic venous insufficiency: a review

José Ángel Barajas Colón1, Juan José Granados-Romero2, Baltazar Barrera-Mera3, Rodrigo Banegas-Ruiz4, José Juan Vargas-Morales4, Elvira Barrera-Calva3, Francisco Fabián Gómez-Mendoza5, Carlos Rubén Baca-Domingúex6, Yuri Jiménez Caprielova7, Emilio Pérez Ortega8, Rodrigo A. Mendoza-Aceves9, Ana Lilia Abundez-Pliego10, Luis David Cortés-Badillo9, Agustín Reyes-Gutiérrez9, Óscar Gómez-Chacón8, Karen Uriarte-Ruiz3, Mariana del Carmen Radilla-Flores12, Nelson Niels Espinosa Queb12, Alejandro Ángel Corona Figueroa12, Bruno Andrés Salazar Trujillo12, Mario Gutiérrez-Hernández13, Alan Isaac Valderrama-Treviño13•8

1Department of Angiology and Vascular Surgery, CMNSXXI, CDMX, Mexico
2Department of Surgery, 3Department of Physiology, Faculty of Medicine, UNAM, CDMX, Mexico
4Department of Traumatology, 5Department of Hand Surgery and Microsurgery, Rehabilitation Hospital, Luis Guillermo Ibarra Ibarra, CDMX, Mexico
5Department of Hand Surgery, Central Military Hospital, CDMX, Mexico
6Department of Surgery, Ángeles Villahermosa Hospital, Mexico
7Faculty of Medicine, UNAM, CDMX, Mexico
8Department of Anaesthesiology, Angeles del Pedregal Hospital, CDMX, Mexico
9Department of Surgery, 10Department of Anaesthesiology, PEMEX General Hospital, Ciudad del Carmen, Mexico
11Department of Plastic Surgery, CENIAQ, CDMX, Mexico
12Department of Surgery, Central North Hospital PEMEX, CDMX, Mexico

Received: 20 April 2021
Accepted: 07 May 2021

*Correspondence:
Dr. Alan Isaac Valderrama-Treviño,
E-mail: alan_valderrama@hotmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Chronic venous insufficiency (CVI) comprises a complete spectrum of morphological and functional abnormalities of the venous system1 including any long-term functional and morphological alteration. CVI accounts for several abnormalities of the venous system. It is a highly prevalent disease that causes serious economic consequences, a decrease in the quality of life and can lead to serious complications. An exhaustive review was performed with the available literature, using the PubMed, ScienceDirect, Scopus and Cochrane databases from 2004 to 2021. The search criteria were formulated to identify reports related to chronic venous insufficiency. The pathophysiology of chronic venous insufficiency begins with chronic venous hypertension and the dilation of the vessel, this leads to a series of pathological changes in the venous wall and surrounding tissues, in advanced stages of CVI, skin lesions are associated with an increased proliferation of skin capillaries and microcirculatory abnormalities that may be the result of an altered level of factors responsible for the angiogenic response, such as vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2) and angiostatin. In this review, updates on pathophysiology, clinic, diagnosis, classification and treatment of this disease are analyzed, with special emphasis on therapeutic options. Chronic venous insufficiency is a disease that affects the patient at several levels, mainly diminishing his/her quality of life. Currently there are various treatments ranging from habit modifications, pharmacological, to endovenous and surgical treatment.

Keywords: Chronic venous insufficiency, Sclerotherapy, Phlebotonics, Vompression stockings, Radiofrequency, Endovenous therapy, Angiology
INTRODUCTION

The classic symptoms include; burning pain, heaviness, tired legs, itching, hot spots “sensation”, restless legs, venous claudication, aesthetic discomfort and signs such as telangiectasia and varicose veins in different presentations. The term chronic venous insufficiency (CVI) refers to an advanced stage of the disease, cases in which there is edema, trophic disorders in the skin and/or the presence of ulcers, it is currently considered a common condition caused by valve dysfunction with or without associated valvular obstruction. Chronic venous disorders of the lower extremities are common vascular pathologies and carry big medical and socioeconomic impact, currently demanding 1–2.5% of medical care budgets in developed countries; they are prevalent in a large part of the world population (prevalence of up to 73% in women and 56% in men) and significantly reduce the quality of life of affected patients.

Methods

An exhaustive review was performed with the available literature, using the PubMed, ScienceDirect, Scopus and Cochrane databases from 2004 to 2021. The search criteria were formulated to identify reports related to chronic venous insufficiency. We use the following keywords: chronic venous insufficiency, sclerotherapy, phlebotonics, compression stockings, radiofrequency, endovenous therapy, angiography. We also include the author's experience in the management of these patients.

Results

The pathophysiology of chronic venous insufficiency begins with chronic venous hypertension and the dilation of the vessel, this leads to a series of pathological changes in the venous wall and surrounding tissues, in advanced stages of CVI, skin lesions are associated with an increased proliferation of skin capillaries and microcirculatory abnormalities that may be the result of an altered level of factors responsible for the angiogenic response, such as vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2) and angiostatin. VEGF is a five-member protein family; however, two of them VEGF-A and VEGF-C have the most increased activity and stimulate vessel formation as well as an increase endothelial cell permeability through the formation of vesicular-vacuolar organelles, providing transport of plasma proteins such as fibrinogen and plasminogen from the bloodstream to the surrounding tissues. Transforming growth factors, particularly the TGF-β family, play a crucial role in the pathophysiology of the vascular wall, both in the early (C2) and late (C6) stages, different isoforms of TGF-β and its signaling receptors can actively participate in the imbalance of matrix metalloproteinases (MMPs) and their inhibitors (tissue metalloproteinase inhibitors (TIMPs) (MMP / TIMP) throughout CVI progression, (proteins widely known for the elastin degradation of the extracellular matrix of the vascular wall and the protective glycosaminoglycan layer of the endothelium), allowing for harmful interaction between leukocytes and the endothelial cell membrane. Angiotensin is an angiogenesis inhibitor, targeting on endothelial cells. It inhibits cell proliferation and migration, stimulates apoptosis, blocks microvascular formation and decreases cellular vessel permeability, plasminogen (PLG), considered a precursor to the formation of pro-inflammatory interleukins such as IL-6, is an important component of the inflammatory cascade related to a variety of vascular diseases.

GLYCOCALYX IN VENOUS DISEASE / VENOUS INSUFFICIENCY

Glycocalyx is a glycosaminoglycan found on the surface of endothelial cells, it is highly relevant as it prevents leukocyte adhesion, inflammation and thrombosis. Mechanical or stress forces in the vein wall lead to injury and loss of glycocalyx, resulting in endothelial dysfunction and expression of adhesion molecules that attract leukocytes, this provoking an inflammatory response “opening the door” to: (a) the mecano-transduction of acute and chronic stimuli; (b) increased permeability barrier; (c) increases harmful adhesion of blood leukocytes, lymphocytes and platelets; and (d) supports the extravasation of reactive blood cells, capable of inducing inflammation and proteolysis in the microenvironment of blood vessels. The understanding of this concept has made possible the development of drugs that target this situation, for example, sulodexide, which enables the healing of venous ulcers, improving symptoms such as pain, heaviness and edema, exerting a systemic effect by interfering with inflammatory chemokines.

RISK FACTORS

Risk factors for the development of progressive chronic venous disease (CVD) and varicose veins include; advanced age, excess body weight, sedentary lifestyles and occupations, family history, and pregnancy Table 1. Poor eating habits and no or little physical activity prevail as the top modifiable factors, these can be mitigated by making lifestyle changes such as stop smoking and increasing physical activity, reducing excess body weight, however, some are not as easily managed, so we must come up with a strategy to treat them. It is believed that constipation stimulates the appearance of CVI due to an increased intra-abdominal pressure, sedentary lifestyle and obesity rise vascular resistance by increasing the weight load in the lower extremities. A study by Pupo et al showed that the age of presentation prevailed between 46 to 55 years (44.9%), followed by 36 to 45 years (20.4%). The female sex having the highest incidence (61.2%). Almost every study shows this predominance of the female sex in a ratio of 5 to 1, attributable to pregnancy and hormonal factors. Authors such as Pupo estimated in their study that 89% of patients have a family pathological history (APF), which they consider as crucial for the development of CVI, followed by chronic constipation (29 for 59.2%); obesity,
sedentary lifestyle (25 for 51.0%), history of deep vein thrombosis (DVT) (22 for 44.9%) and multiparity (20 cases for 40.8%).

**Table 1: Risk factors for chronic venous insufficiency.**

| Modifiable factors   | Non-modifiable factors |
|----------------------|------------------------|
| Increased BMI        | Advanced age           |
| Smoking              | Family history of venous disease |
| Sedentary life       | Ligament laxity        |
|                      | Trauma in lower limb   |
|                      | Previous venous thrombosis |
|                      | Pregnancy              |
|                      | Female gender          |

**CLASSIFICATION**

To address the complexity of the clinical manifestations of chronic venous disease, a standardized classification system called CEAP was created, it takes into account the pathology, natural and clinical history of this disease. CEAP was created in 1996, revised in 2004 and updated in 2020. The letter C refers to the clinic presentation, within this category is C0, which refers to the absence of visible or palpable signs of venous disease, C1 telangiectasias or reticular veins, C2 varicose veins, to these categories you can add the letter “S” when they are symptomatic or “a” in case of being asymptomatic and the letter “r” in case of recurrence.

Finally, there is category C6 that represents an active venous ulcer. The letter E refers to the classification of etiology, and may be; primary, congenital, unidentified and secondary intravenous and extravenous. The letter A refers to the classification of the anatomical sites of venous disease, which can be superficial, deep, perforating or unidentified, here we can specify the affected venous segment.

Finally, the letter P refers to the pathophysiological classification, including reflux, obstruction, reflux or obstruction and no identified pathophysiology.

**CLINICAL MANIFESTATIONS**

The clinical manifestations of CVI vary (Table 2) from telangiectasias or “spider veins”, reticular veins, large varicose veins to venous stasis ulcers, in advanced CVI: pain, edema, itching, hyperpigmentation, eczema, lipodermatosclerosis, scarred or active ulcers, white atrophy. There may also be episodes of superficial and deep thrombophlebitis. The patient may report pain, heaviness or cramps in the distal portion of the legs.

**COMPLICATIONS**

One of the major complications in chronic venous insufficiency is the appearance of venous ulcers, which have a prevalence of 0.7%, it can be associated with thromboembolic events, 18-25% of patients can present deep vein thrombosis and it has been reported that up to 7% could present pulmonary embolism, as well as up to a 50% probability of developing post-thrombotic syndrome. The probability can be determined documenting the signs and symptoms of chronic venous insufficiency that develop after deep vein thrombosis.

**Table 2: Clinical manifestations for chronic venous insufficiency.**

| Signs                   | Symptoms       |
|-------------------------|----------------|
| Hyperpigmentation       | Pain           |
| Eczema                  | Itching        |
| Lipodermatosclerosis    | Heaviness      |
| Ulcers                  | Cramps         |
| White atrophy           |                |
| Thrombophlebitis        |                |
| Telangiectasias         |                |
| Varicose veins          |                |
| Edema                   |                |

**Table 3: Complications of chronic venous insufficiency.**

| Complications        | Diagnosis       | Treatment                                      |
|----------------------|-----------------|------------------------------------------------|
| Venous ulcers        | Clinical        | Debridement of the ulcer, dressings and compression stockings |
| Superficial thrombophlebitis | Clinical and ultrasound | Supportive measures, elevation of the limb, compression stockings, analgesics |
| Deep vein thrombosis | Clinical and ultrasound | Anticoagulation, thrombolysis, thrombectomy or inferior vena cava filter |
| Post-thrombotic syndrome | Clinical and ultrasound | Supportive measures or percutaneous angioplasty |
| Pulmonary embolism   | Clinical pretest probability, D-dimer, CT | Anticoagulation, ventilatory and hemodynamic stabilization |

**DIAGNOSIS**

The diagnosis of chronic venous insufficiency is initially based on the clinical presentation, followed by the physical examination and using the duplex ultrasound (gold standard) for confirmation. This is a simple, inexpensive and minimally invasive method that allows to examine the
morphology and functionality of the venous system. As vein compression is performed, as well as reflux time quantification of incompetent veins. It is considered an incompetent vein if its backflow time is greater than 0.5 seconds for superficial or perforating veins and more than 1 second for deep veins.27

**TREATMENT**

Surgical methods based on intraluminal fibers (radiofrequency, laser, glue, water vapor) used alone or together, do not manage to completely eliminate all the varicose veins in an extremity, it is not uncommon for incompetent veins to persist and these neglected veins are often responsible for recurrences. The key to therapeutic success in the treatment of venous insufficiency lies in the treatment of venous hypertension and in the complete, rigorous and confirmed elimination of all leg, ankle and foot varicose veins.28

**COMPRESSION SOCKS**

Compression stockings are often the first line of treatment for varicose veins in people without healed or active venous ulcers. There are different lengths, from knee to full stockings, and apply different gradient of pressure to support blood flow. In the veins, however there is insufficient high-quality evidence to determine whether compression stockings are effective as a sole and initial treatment or whether any type of sock is superior to any other. Conclusions from individual studies regarding the optimal pressure provided by stockings were conflicting, although results from one study suggested that low-pressure stockings (>20 mmHg) may be as effective as higher-pressure stockings (30 to 40 mmHg) to alleviate symptoms. Some authors assure that stronger compression does not deliver more benefits, so we use moderate compression stockings, never more than 23 mmHg.28 Regarding the optimal length of the stockings were inconclusive despite the fact that no serious or lasting side effects were observed.29

**PHLEBOTONICS**

Natural or synthetic phlebotonics along with compression stockings, are considered the first pharmacological line for symptomatic treatment of varicose veins, reducing capillary permeability, releasing inflammation mediators and improving the overall venous vessel tone.30 In a randomized study from Zapata et al there was a comparison between the use of phlebotonics and placebo, where moderate-quality evidence shows that phlebotonics may have beneficial effects on edema and improve some specific signs and symptoms (quality of life) related to CVI, such as trophic disorders, cramps, restless legs, swelling and paresthesia. However, compared with placebo, they also produce more adverse effects, being gastrointestinal disorders the most frequent one. In an interesting conclusion, phlebotonics did not show advantages compared to placebo in ulcer healing.4 Diosmin is a natural compound, a flavonoid, commonly found in citrus fruits and in the Rutaceae family. It has been shown to improve lymphatic drainage, support microcirculation and increase venous tone and elasticity it also has an anti-inflammatory effect relieving oxidative stress, it is considered an important therapeutic tool in the treatment strategy of chronic venous disorders.31-35 In a study, Feldo et al denoted that oral administrations of 600 mg of diosmin twice daily for three month significantly decreased the plasma level of selected pro-inflammatory and pro-angiogenic factors, for example, TNF alpha, IL-6, FGF2, VEGF-A and VEGF-C. It could affect the reduction of interstitial edema, the reduction of the inflammatory stage and pain, and the negative regulation of the processes related to VEGF.36 Other flavonoids that have also been studied are rutin, grape seed extract, hydrosmin, ruscus and Indian chestnut. It has been documented that Ruscus aculeatus decreases the diameter of the deep veins and reduces edema of the affected limb and venous stasis. The horse chestnut reduces edema of inflammatory or lymphatic origin and inhibits enzymatic and non-enzymatic peroxidation.37

**COMBINED PHLEBOTONICS**

A study carried out by Cabrerizo et al showed beneficial effects when combining Aescin with procyanidin in patients with CVI, they assessed the changes in patients treated through quality of life questionnaires and by determining the safety of this association (SF-36v2 and VEINES -QOL / SYM), the results showed that the VEINES-SYM questionnaire significantly improved in the parameters "swollen legs", "night cramps", "heat / burning" and "restless legs" compared to the usual care group, however significant differences were not detected compared to the usual care group (monotherapy).38 Diosmin / hesperidin are two flavonoids, they are micronized to increase absorption, this combination has showed several benefits with fewer adverse effects, they reduce symptoms such as pain, heaviness and paresthesia, improve skin changes and overall quality of life.39 Calcium dobesilate acts along the endothelium and in the capillary’s base membrane by blocking hyperpermeability, inhibiting blood hyperviscosity and platelet aggregation, showing long-term benefits in chronic venous disease.40

**SCLEROTHERAPY**

Sclerotherapy is a minimally invasive technique that has been used for over a hundred years being especially useful for treating small caliber veins. However, it also has several limitations such as dilution disparities, its progressive inactivation and the inaccuracy of the desired effect once injected in the blood vessel. These glitches have been replaced by placing these liquids in the vessel periphery in the form of microbubbles, physically displacing the blood contained in the vessel and making it easier to have the desired effect in the corresponding
segment (foam sclerotherapy). Because of its proven efficacy color Echo-Doppler-guided micro foam sclerotherapy is the treatment of choice when the anatomical and functional removal of pathological venous defect is indicated. Nevertheless, recent publications have exposed cases of air embolism with ischemic and cerebrovascular symptoms after the administration of homemade foams, rising the concern for the safety of their use without following strict precautions. Reticular veins are subdermal veins located in the lower limbs and are mainly associated with aesthetic complaints. Although sclerotherapy is the treatment of choice for reticular veins in the lower limbs, no consensus has been reached regarding the optimal sclerosant. The recommendations of the Tegernsee Consensus, dictate the moderate maximum recommended volume to be injected.

ENDOVENOUS TREATMENT

There are two main options for endovenous treatment, radiofrequency ablation (RFA) and endovenous laser therapy (EVLT), both techniques are especially useful when dealing with veins that follow a straight path and/or do not have a complex anatomy. Its main advantage is using an advanced endoluminal catheter that can be ultrasound guided to the site of venous incompetence, commonly below the epigastric valve at the saphenous-femoral valve. These are energy-based therapies and produce endothelial damage that leads to fibrotic occlusion and ultimately to the vein ablation. These are minimally invasive procedures that could even be performed under local anesthesia. Among its adverse effects we find; pain, ecchymosis, edema, hematomas, superficial thrombophlebitis, hyperpigmentation of the skin, paresthesia. Severe but rare adverse effects are deep vein thrombosis, pulmonary embolism and endovenous heat-induced thrombosis. Endovenous therapy is currently considered the first line of treatment in superficial venous incompetence according to the 2013 NICE guidelines and the 2016 American College of Phlebology guidelines, being open surgery the second-best option.

RADIOFREQUENCY

 Extraction of the saphenous vein by classic surgical open treatment causes morbidity, disability and increased recurrences, consequently the use of endovascular methods offers an effective and safe alternative to conventional procedures. A study carried out by Jiménez and Quiroga in 2016 evaluated the use of radiofrequency in the treatment of varicose veins in the lower limbs. Using the visual analog scale of pain and echo-Doppler, they evaluated pain during and after the procedure, use of analgesics, postoperative complications, ulcer healing, work incapacity and how long it took to fully return to work activities, it was concluded that the use of radiofrequency for the treatment of varicose veins is an effective and safe method, the patients returned to their activities in an average of 5 to 7 days, with little use of analgesics; patients with venous ulcer were fully healed at 3 months in 95% of cases and no complications or clinical recurrence or by echo-Doppler were reported in the follow-up, facilitating the early return to work activities of the patients, mainly in those who had contraindications for having a surgical procedure.

Complete resolution can only be achieved when we can be reasonably sure that all veins that may constitute a source of recurrence have also been removed. The deep anatomical and functional knowledge that echo-Doppler provides, makes it an elemental tool to reach this goal, when used to perform exhaustive examinations in subsequent visits, between 3 and 5 months, after the first treatment. During this period is when we start treating newly and recanalized veins that are also detected in the 6,9- and 12-month follow-up consultations. Surgery or endoluminal techniques are of no use here, since varicose disease is considered an essentially evolutionary condition; however, the correct application of treatment can abruptly reduce its recurrence.

LASER

Endovenous laser therapy is a novel form of venous ablation. This method uses thermal energy to produce endothelial damage leading to fibrotic occlusion and ablation of the vein. Ultrasound guidance and local anesthesia are used to place a catheter in the saphenous vein, a laser fiber is then introduced and positioned below the saphenous femoral junction. Local anesthesia is injected and the fiber is slowly withdrawn while the energy of the diode laser (having a wavelength between 810 and 1054 nm) is applied in short pulses. This action is repeated throughout the vein until it shuts the saphenous femoral coupling and the access point.

LASER OR RADIO FREQUENCY?

Both techniques are recommended as the first choice of treatment for saphenous and accessory vein insufficiency according to the 2016 American College of Phlebotomy guidelines, as well as the 2013 NICE guidelines. The authors Ahadiat et al, in 2018 set out to compare endovenous laser therapy and radiofrequency ablation, obtaining the following results. Regarding the effectiveness of the method, defined as the closure of the vein, evaluated in subsequent visits by using ultrasound, both techniques are effective, however the laser showed a better outcome. They found that when using radiofrequency there were fewer cases of pain associated with the procedure, as well as less ecchymosis compared to the laser. This may be due to the fact that the laser reaches higher temperatures in a shorter period of time, unlike radiofrequency, which has longer plateau phases and lower temperatures. Concerning complications such as deep vein thrombosis and pulmonary embolism, no significant difference was found between the two techniques. As for recurrence defined as recanalization of the vein followed by venous incompetence, the laser
method had fewer manifestations. Finally, in terms of satisfaction and quality of life, no statistically significant difference was found between both techniques.59

WHAT METHOD TO CHOOSE?

In order to make the best choice possible we have considered the anatomical characteristics and underlying diseases, as well as the particular wishes of the patients.

However, guidelines have already been created to help us offer the correct treatment to patients with chronic venous insufficiency. The 2013 NICE guidelines recommend endovenous radiofrequency or laser therapies as the first line of treatment, ultrasound-guided sclerotherapy as a second line, and finally surgical treatment with high ligation and saphenectomy as a third line.50 The American College of Phlebology in 2016 recommended endovenous ablation therapy as the treatment of choice for incompetent saphenous and accessory veins and surgery in veins that are not susceptible to endovenous procedures, although it is associated with increased pain, convalescence, and morbidity. Treatment for anterior or posterior non-truncal, refluxing tributary, or circumflex veins is more complex as we must evaluate its competence, size, tortuosity and depth in relation to the skin. It is recommended that visible veins be treated with phlebectomy or sclerotherapy. In patients where the root of the disease is perforating reflux, treatment with endovenous ablation, ligation, or ultrasound-guided sclerotherapy is suggested. However, we must remember that we treat patients and not diseases thus treatment must be personalized, appropriate to the patient, contemplating the financial resources and the work environment in which we operate.

DISCUSSION

In Mexico, the first contact doctor (general practitioner and family doctor) does not have an essential minimum preparation in CVI since the study program of the main medical schools does not include an angiology subject and the student does not learn the basic elements to diagnose CVI. In family medicine, the only drugs to be prescribed within the institution are pentoxifylline and ASA, since there are no phlebotonic drugs in the public health sector, there is generally a misuse of anticoagulants, antithrombotics, antiplatelet agents and diuretics.51 Various studies show that varicose disease is highly progressive. Labropoulos et al studied cases of progression in patients who waited or delayed elective varicose vein surgery, it was performed in 116 lower extremities of 90 patients, a duplex ultrasound where the reflux detected was the predominant pathology and was present in 97.4% of the extremities. After a second ultrasound performed 1 to 43 months later, the disease had progressed in 31 extremities (26.7%), of which 14 (12.1%) had a new reflux site and 17 (14.7%) had an extension of the pre-existing reflux. Thirteen limbs (11.2%) had progressed to a new clinical stage: seven went from C2 to C3, four from C3 to C4, and two from C4 to C6; However, new reflux was detected in only seven of these extremities.52

We consider early treatment of varicose veins in the first medical contact a priority, as it reduces costs and time when treating their complications (active ulcer, chronic ulcer, infection, work incapacity and decreased quality of life). Spot on and early screening will allow the doctor and specialist to intervene mainly to improve the modifiable risk factors and so avoid long-term complications.

CONCLUSIONS

Chronic venous insufficiency is a disease that affects the patient at several levels, mainly diminishing his/her quality of life. Currently there are various treatments ranging from habit modifications, pharmacological, to endovenous and surgical treatment. We must have an extensive knowledge of the pathology to offer the best course of treatment, always considering the characteristics and special requirements of each patient.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg. 2009;498-501.
2. Nicolaitides A, Kakko S, Baekgaard N, Comerota A, Maeseneer M, Eklof B, et al. Management of chronic venous disorders of the lower limbs. Int Angiol. 2018;181-254.
3. Miquel C, Rial R, Ballesteros MD, García C. Practice guidelines in chronic venous disease from the Phlebology and Lymphology Working Group of the Spanish Society of Angiology and Vascular Surgery. Angiología. 2016;55-62.
4. Martínez-Zapata MJ, Vernooij RWM, Urioña Tuma SM, Stein AT, Moreno RM, Vargas E, et al. Flebotónicos para la insuficiencia venosa. Cochrane. 2016.
5. Shabani Varaki E, Gargiulo Gaetano D, Penkala S, Breen PP. Peripheral vascular disease assessment in the lower limb: a review of current and emerging non-invasive diagnostic methods. Biomed Eng Online. 2018;(17):61.
6. Castro-Ferreira R, Cardoso R, Leite-Moreira A, Mansilha A. The Role of Endothelial Dysfunction and Inflammation in Chronic Venous Disease. Ann Vasc Surg. 2018;46:380-93.
7. Khushbu R, Sawan KJ, Jeltsch M. Biology of Vascular Endothelial Growth Factor C in the Morphogenesis of Lymphatic Vessels. Front Bioeng Biotechnol. 2018;12:6:7.
8. Serralheiro P, Soares A, Costa Almeida C.M, Verde I. TGF-β1 in Vascular Wall Pathology: Unraveling Chronic Venous Insufficiency Pathophysiology. Int J Mol Sci. 2017;(18)12:2534.

9. Serralheiro P, Novaes A, Cairão E, Maia C, Costa Almeida CM, Verde I. Variability of MMP/TIMP and TGF-β1 Receptors throughout the Clinical Progression of Chronic Venous Disease. Int J Mol Sci. 2017;19(1):6.

10. Kucukguven A, Khalil R. Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets. 2013;14:287-324.

11. Soff GA. Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev. 2000;19:97-107.

12. Feldo M, Wójciak-Kosior M, Sowa I, Kocki J, Bogucki J, Zubilewicz T et al. Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis. Molecules. 2019;24(18):3316.

13. Mannello F, Raffetto JD. Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research. Am J Transl Res. 2011;149-58.

14. Mannello F, Medda V, Ligi D. Glycosaminoglycan sulodexide inhibition of mmp-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol. 2013;354-65.

15. Daniela Ligi, Lídia Croce, Ferdinando Mannello. Chronic Venous Disorders: The Dangerous, the Good, and the Diverse. Int J Mol Sci. 2018;19(9):2544.

16. Bignamini, Jiri M. Sulodexide for the symptoms and signs of chronic venous disease: a systematic review and metaanalysis. Adv Ther. 2020;1013-33.

17. Labropoulos N. How Does Chronic Venous Disease Progress from the First Symptoms to the Advanced Stages? A Review. Adv Ther. 2019;36(1):13-9.

18. Milena SP, Alberto dR, Alejandro GM. Caracterización de la insuficiencia venosa crónica profunda por refluo valvular. Revista Archivo Médico de Camagüey. 2014;18(1):30-4.

19. Silva MA, Burihan CM, Barros C, Nasser F, Ingrund JC, Nesen A. Resultados do tratamento da Insuficiência Venosa Crónica grave com espuma de polidocanol guiada por ultrassom. J Vasc Bras. 2012;11(3).

20. Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H, et al. The 2020 update of the CEAP classification system and reporting standars. J Vasc Surg Venous Lymphat Disord. 2020;342-52.

21. Dua A, Heller JA. Advanced Chronic Venous Insufficiency. Vasc Endovascular Surg. 2017;12-6.

22. Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. 2014;333-46.

23. Rabe E , Pannier-Fischer F, Bromen K et al. Bonner Venenstudie der Deutschen Gesellschaft für Phlebologie . Phlebology. 2003;1-14.

24. Bozoglan O, Mese B, Eroglu E, Erdogan MB. Comparison of endovenous laser and radiofrequency ablation in treating varicose veins in the same patient. Vasc Endovascular Surg. 2016;50:47-51.

25. Benarroch-Gannel J, Sheffield KM, Boyd CA, Riall TS. Analysis of venous thromboembolic events after saphenous ablation. J Vasc Surg Venous Lymphat Disord. 2013;26-32.

26. Rhee SJ, Cantelmo NL, Conrad MF, Stoughton J. Factors influencing the incidence of endovenous heat-induced thrombosis (EHIT). Vasc Endovascular Surg. 2013;207-12.

27. Coleridge-Smith P, Labropoulos N, Parshc H. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs--UIP consensus document. Part I. Basic principles. Eur J Vasc Endovasc Surg. 2006;31:83.

28. Garrido CJ. La escleroterapia con espuma es un método eficaz para el tratamiento de la insuficiencia venosa. Angiología. 2016;206-17.

29. Shingler S, Robertson L, Boghossian S, Stewart M. Compression stockings for the initial treatment of varicose veins in patients without venous ulceration. Cochrane Database Syst Rev. 2011;9(11):CD008819.

30. Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Gloviczki ML, et al. The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;25:48S.

31. Bogucka-Kocka A, Woźniak M, Feldo M, Kocki J, Szewczyk K. Diosmin–isolation techniques, determination in plant material and pharmaceutical formulations, and clinical use. Nat Prod Commun. 2013;545-50.

32. Liu WY, Liou SS, Hong TY, Liu IM. The Benefits of the Citrus Flavonoid Diosmin on Human Retinal Pigment Epithelial Cells under High-Glucose Conditions. Molecules. 2017;22(12):2251.

33. Batchvarov IV, Batseleva MG, Danyano II. One-year diosmin therapy (600 mg) in patients with chronic venous insufficiency – results and analysis. J Biomed Clin Res. 2010;3(1):5154.

34. Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs. 2003;63(1):71-100.

35. Tong N, Zhang Z, Zhang W, Qiu Y, Gong Y, Yin L et al. Diosmin Alleviates Retinal Edema by Protecting the Blood-Retinal Barrier and Reducing Retinal Vascular Permeability during Ischemia/Reperfusion Injury. PLoS ONE. 2012;8(4):e61794.

36. Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uronia Tuma SM, Stein AT, Moreno Carriiles RMM, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020;(3)11:CD003229.
37. Lichota A, Gwozdzinski L, Gwozdzinski K. Therapeutic potential of natural compounds in inflammation and chronic venous insufficiency. Eur J Med Chem. 2019;68-9.
38. Cabrerizo CF, Aranda Granados P., García Ruíz A. Effectiveness and safety of esicine/procyanidine combination in chronic venous insufficiency. Cardiocare. 2018;173-81.
39. Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37:143.
40. Ciapponi A, Laffaire E, Roque M. Calcium Dobesilate for chronic venous insufficiency: a systematic review. Angiology. 2004;55(2) 147-54.
41. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg. 2001;27:58-60.
42. Bertanha M, Jaldin RG, Moura R, Pimenta RF, Mariúba JO et al. Sclerotherapy for Reticular Veins in the Lower Limbs: A Triple-Blind Randomized Clinical Trial. JAMA Dermatol. 2017;153(12):1249-55.
43. Breu FX, Guggenbichler S, Wollmann JC. 2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany. Vasa. 2008:1-29.
44. Carruthers TN, Farber A, Rybin D, Doros G. Interventions on the superficial venous system for chronic venous insufficiency by surgeons in the modern era: an analysis of ACS-NSQIP. Vasc Endovascular Surg. 2014;48:482-90.
45. Jiménez C, Quiroga F. Radiofrequency in the treatment of varicose veins of the lower limbs. A prospective study of 176 patients in Bogotá. Angiología. 2017;69 (2):89-97.
46. Vuylsteke ME, Martinelli T, Van Dorpe J. Endovenous laser ablation: the role of intraluminal blood. Eur J Vasc Endovasc Surg. 2011;42:120-6.
47. Varicose veins: diagnosis and management. NICE guidelines. 2013.
48. Gibson K, Khilnani N, Schul M, Meissner M. American College of Phlebology Guidelines—treatment of refluxing accessory saphenous veins. Phlebology. 2016;448-52.
49. Ahadiat O, Higgins S, Ly A, Nazemi A, Wysong A. Review of endovenous thermal ablation of the great saphenous vein: endovenous laser therapy versus radiofrequency ablation. Dermatol Surg. 2018;679-88.
50. Schuller-Petrovic S. Endovenous ablation of saphenous vein varicosis. Wien Med Wochenschr. 2016;297-301.
51. Espejel-Blancas JA, Chinchilla-Hernández RAJ, Garcés-Martínez MAG. Insuficiencia venosa crónica y enfermedad hemorroidal en México: Opinión de expertos. Rev Mex Angiol. 2018;204-12.
52. Labropoulos N, Leon L, Kwon S, Tassiopoulos A, Gonzalez-Fajardo JA, Kang SS, et al. Estudio de la progresión del reflujo venoso. J Vasc Surg. 2005:291-5.

Cite this article as: Colón JAB, Granados-Romero JJ, Barrera-Mera B, Banegas-Ruiz R, Vargas-Morales JJ, Barrera-Calva E, et al. Chronic venous insufficiency: a review. Int J Res Med Sci 2021;9:xxx-xx.